The Merger closed on May 21, 2025. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of ACELYRIN, par value $0.00001 per share (collectively, the "ACELYRIN Shares"), was cancelled and converted into the right to receive 0.4814 shares of Common Stock of the Issuer, without interest and, if applicable, cash in lieu of fractional shares, without interest, subject to any applicable withholding. Accordingly, at the Effective Time of the Merger, the AyurMaya Fund received, in exchange for its 9,334,735 ACELRYIN Shares, approximately 4,493,741 shares of Common Stock, as disclosed to the Reporting Persons by the Issuer. The Reporting Persons will file an amendment to the Schedule 13D to the extent the actual number of shares of Common Stock received differs materially from the foregoing. The foregoing summary of the transaction that was consummated pursuant to the Merger Agreement does not purport to be complete and is qualified in its entirety by, the full text of the Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on May 21, 2025, and is incorporated herein by reference.